

14 BIBLIOGRAFÍA

- Center, Japan Chemical Information Link. (14 de mayo de 2013). *Spectral Database for Organic Compounds SDBS*. (AIST, Producer) Retrieved 23 de abril de 2015 from http://sdbs.db.aist.go.jp/sdbs/cgi-bin/direct_frame_disp.cgi?sdbno=40172
- León Iza, M., & Zarain Herzberg, Á. (2010). *El ion calcio como segundo mensajero en el desarrollo del sistema nervioso*. Universidad Nacional Autónoma de México, Departamento de Bioquímica, México D.F.
- Lopez, T., Bata García, J. L., Esquivel, D., Ortiz-Islas, E., Gonzalez, R., Ascencio, J., et al. (2010). Treatment of Parkinson's disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system. *International Journal of Nanomedicine* (6), 19-31.
- Correale, J., Garcea, O., Villa, A., Melamud, L., & Rugilo, C. (2011). Esclerosis Múltiple, Neuromielitis Óptica y Otras Enfermedades Desmielinizantes. In J. Corrales, O. Garcea, & A. Villa, *Neuroinmunología Clínica* (pp. 127-164). Buenos Aires, Argentina: Editorial Medica Panamericana.
- Correale, J., Villa, A. M., & Garcea, O. (2011). *Neuroinmunología Clínica*. Buenos Aires, Argentina: Editorial Médica Panamericana.
- Lucchinetti C, B. W. (2000). Heterogeneity of multiple sclerosis lesions: implications of pathogenesis of demyelination. *Ann Neurol* (55), 458-467.
- López Goerne, T. M. (2011). *Nanotecnología y Nanomedicina: La ciencia del Futuro... Hoy*. Ciudad de México, Distrito Federal, México: Arkhé Ediciones.
- López Goerne, T. M. (15 de abril de 2015). Sol-Gel. (H. Sánchez de Cima Carrillo, Interviewer) Ciudad de México, México.
- López, T., Ortiz, E., Meza, D., Basaldella, E., Bokhimi, X., & al., e. (2011). Controlled release of phenytoin for epilepsy treatment for tania and silica based materials. *Mater Chem Phys* (126), 922-929.
- Córdoba García, F. (2005). *Fundamentos biológicos del aprendizaje y la memoria*. Universidad de Huelva, Departamento de Biología Ambiental y Salud Pública.
- Allen, J., Bruss, J., & Damasio, H. (2004). The Structure of the Human Brain. *American Scientist* , 92, 246-253.
- Andrade Guel, M. L., Díaz Jiménez, L., & Cortes Herdández, D. (2013). Materiales nanoestructurados cerámicos como vehículo para la liberación de principios activos. *Avances en Química* , 8 (3), 171-177.
- Antunes, A. F. (2013). Trends in Nanopharmaceutical Patents. *International Journal of Molecular Sciences* (14), 7016-7031.
- Aoife, C. M. (1999). Rapid analysis of the expression of heterologous proteins in Escherichia coli using pyrolysis mass spectrometry and Fourier transform infrared spectroscopy with chemometrics: application to $\alpha 2$ -interferon production. *Journal of Biotechnology* (72), 157-167.
- Babak Jalilian, H. B.-J. (2012). Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Copolymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System? *International Journal of Molecular Sciences* (13), 14579-14605.
- Banks, W. A. (1999). Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. *Journal of Neurovirology* , 5, 538-555.
- Barkovich, J. (2000). Concepts of Myelin and Myelination in Neuroradiology. *American Journal of Neuroradiology* , 21, 1099-1109.
- Biblioteca Nacional de Medicina de EE.UU. (18 de 04 de 2013). *MedlinePlus*. (S. A. Goldman L, Editor, & I. N. Salud, Producer) Retrieved 28 de 01 de 2015 from Enciclopedia Médica: nlm.nih.gov
- Brockes, J. (Marzo de 1982). Myelin, and Multiple Sclerosis. *Engineering & Science* , 9-14.
- Dai, H., Navath, R. S., & Balakrishnan, B. (2010). Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration. *Nanomedicine* , 5 (9), 1317-1329.
- Fattovich G, G. G. (1996). A survey of adverse events in 11, 241 patients with chronic hepatitis treated with alpha interferon. *J Hepatol* (24), 38-47.
- Feynman, R. (1959). There is plenty of room at the bottom. *American Physical Society*. Pasadena.
- Filley, C. (1 de Enero de 2005). *Why the White Brain Matters*. Retrieved 6 de Abril de 2015 from The Dana Foundation: <http://www.dana.org/Cerebrum/Default.aspx?id=39152>
- Fung, L. K., Ewend, M. G., Sills, A., Sipos, E., Thompson, R., Watts, M., et al. (1998). Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. *Cancer Research* , 58, 672-684.
- Gabathuler, R. (2010). Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. *Neurobiology of Disease* , 37, 48-57.
- Hall, R. (1998). *The Neuron*. Missouri University of Science and Technology, Neuroscience.
- Harvard University. *Structure and Function of Synapses*. Harvard University.

- Jacobs L, O. J. (1981). Intrathecal interferon reduces exacerbations of multiple sclerosis. *Science* (214), 1026-1028.
- Jouyban, A., & Soltani, S. (2012). Blood Brain Barrier Permeation. (B. Acree, Ed.) *Toxicity and Drug Testing* .
- Korsmeyer, R., & Peppas, N. (1984). Solute and penetrant diffusion in swellable polymers. Drug release from glassy poly. *J Control* , 1, 89-98.
- Kreuter, J. (2012). Nanoparticulate systems for brain delivery of drugs. *Advanced Drug Delivery Reviews* (64), 213-222.
- Macalester College. (n.d.). *Neurotransmission*. Retrieved 2 de Abril de 2015 from Biochemistry of Methamphetamine: http://www.macalester.edu/academics/psychology/what_hap/ubnnp/meth08/biochemistry/neurotransmission.html
- Malarkey, E. B., & Parpura, V. (2010). Carbon nanotubes in neuroscience. (Z. Czernicki, Ed.) *Brain Edema XIV* , 337-341.
- Marin, E. B. (2013). Critical evaluation of biodegradable polymers used in nanodrugs. *International Journal of Nanomedicine* (8), 3071-3091.
- Martinelli Boneschi, F. R., Johnson, K., Miller, A., Wolinsky, J., & Ladkani, D. (2003). Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. *Mult. Scler* (9), 349-355.
- Matamala, F. (2011). *Neurohistología*. Universidad de La Frontera, Neuroanatomía.
- Miller, A., Spada, V., Beerkircher, D., & Kreitman. (2008). R.R. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Mult. Scler.* , 494-499.
- Minagar, A., & Alexander, S. (2003). Blood-brain barrier disruption in multiple sclerosis. *Multiple Sclerosis* , 9, 540-549.
- Ministerio de Salud del Perú. (03 de Abril de 2015). *Copaxone*. Retrieved 03 de Abril de 2015 from Biblioteca Farmacologica: <http://www.minsa.gob.pe/portabiblioteca2/biblio/plm/PLM/productos/47846.htm>
- Modi, G., Pillay, V., & Choonara, Y. E. (2010). Advances in the treatment of neurodegenerative disorders employing nanotechnology. *Annals of the New York Academy of Sciences* , 1184, 154-172.
- National Institutes of Health. (2010). *The Brain: Understanding Neurobiology Through the Study of Addiction*. Colorado Springs, U.S.A.: The NIH Curriculum Supplement Series.
- Pajaro Castro, N., Olivero Verbel, J., & Redondo Padilla, J. (2013). Nanotecnología aplicada a la medicina. *Revista Científica Guillermo de Ockham* , 11 (1), 125-133.
- Pascual-Garvi, J. M., González-Llanos, F., Prieto-Arribas, R., Cerdán, S., & Roda, J. M. (2004). La barrera hematoencefálica: desarrollo de una estructura que permite la heterogeneidad funcional del sistema nervioso central. *Revista de Neurología* , 38 (6), 565-581.
- Petros, R. A., & Desimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. *Nature Reviews Drug Discovery* , 9 (8), 615-627.
- Quarles, R., & Morell, P. (2006). Myelin Formation, Structure and Biochemistry. In A. S. Neurochemistry, *Basic Neurochemistry: Molecular, Cellular and Medical Aspects*. Philadelphia: Elsevier, Inc. .
- Ramos Bello, D., & Ramos Niembro, F. (2007). Interferón: 50 años después (1957-2007). *Gaceta Médica de México* , 144 (1), 55-65.
- Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010). Targeting of drugs and nanoparticles to tumors. *Journal of Cell Biology* , 188 (6), 759-768.
- Scott, W., & Barrett, T. (2010). *A Potential Application of Nanotechnology in the Treatment of Multiple Sclerosis* . University of Nottingham. UK: Medlink.
- Sayilkan, F., Asilturk, M., Sayilkan, H., Onal, Y., Akarsu, M., & Ertugrul Arpaç. (2005). Characterization of TiO₂ Synthesized in Alcohol by a Sol-Gel Process: The Effects of Annealing Temperature and Acid Catalyst. *Turk J Chem* (29), 697 – 706.
- Simonis, F., & Schilthuisen, S. (2006). *Nanotechnology, innovation opportunities for tomorrow's defence* . USA: TNO Science & Industry .
- Society for Neuroscience. (2012). *Brain Facts. A primer on the brain and nervous system*. Washington, DC, USA: BrainFacts.
- Stephen D Miller, D. R. (2012). Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. *Nature biotechnology* (30), 1217-1224.
- Stufflebeam, R. (2008). *Neurons, Synapses, Action Potential, and Neurotransmission*. Retrieved 23 de Febrero de 2015 from Consortium on Cognitive Science Instruction: http://www.mind.ilstu.edu/curriculum/neurons_intro/neurons_intro.php
- ter Meulen V, K. M. (1997). The proposed viral etiology of multiple sclerosis and related demyelinating diseases. In K. M. ter Meulen V, & M. H. Raine CS (Ed.), *Multiple Sclerosis Clinical and Pathogenetic basis* (pp. 287-306). Londres, Reino Unido: Chapman & Hall Medical.
- Tessy Lopez, R. G. (2003). Determination of Basic Sites by CO₂ Thermal Programmed Desorption on Sol- Gel CaO-SiO₂ Mixed Oxides. *XII International Workshop on Sol-Gel Science and Technology*. Sydney: Sol-Gel.
- Tessy López, E. O.-I. (2013). Occlusion of INTERFERON® and COPAXONE® on SBA-15 Silica Reservoirs for their Use in the Treatment of Demyelination Diseases . *Journal of Nanomaterials & Molecular Nanotechnology* , 2 (4).

- Toescu, E., & Verkhratsky, A. (2007). The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. *Aging Cell*, 6, 267-273.
- Torres Morera, L. (2001). *Tratado de Anestesia y Reanimación*. Madrid, España: Arán Ediciones S.A.
- WebMD Health Professional Network. (01 de 09 de 2014). *WebMD*. Retrieved 03 de 03 de 2015 from Medscape: http://search.medscape.com/reference-search?queryText=Interferon&navState=3173+4294929305&sortBy=&fromMonth=&fromYear=&toMonth=&toYear=&dateDimId=&CMEDimId=&pagerOffset=0&search_type=&contentType=Drugs
- Werner P, P. D. (2001). Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. *Ann Neurol* (50), 169-180.
- Xinchang Yueding Chemical Co., Ltd. (n.d.). *Xinchang Yueding Chemical Co., Ltd.* Retrieved 20 de abril de 2015 from Hangzhou Yueding Technology Co., Ltd.: <http://www.xcyueding.com/en/proshow.asp?id=678&cla=7,2&leid=3>
- Zarco, L. A. (2014). Bases neurofisiológicas de la conducción nerviosa y la contracción muscular y su impacto en la interpretación de la neuronografía y la electromiografía. *Guía Neurología* 7 .
- Zhuravlev, L. (21 de febrero de 2000). The surface chemistry of amorphous silica. Zhuravlev model. *Colloids and Surfaces*, 1-38.

